Price Alert

Viridian Therapeutics Inc... (VRDN)

NASDAQ: VRDN · Real-Time Price · USD

21.65

0.43 (2.03%)

At close: Oct 03, 2025, 3:59 PM

21.62

-0.14%

After-hours: Oct 03, 2025, 07:03 PM EDT

2.03% (1D)

Bid	20.82
Market Cap	1.77B
Revenue (ttm)	305K
Net Income (ttm)	-344.06M
EPS (ttm)	-3.57
PE Ratio (ttm)	-6.06
Forward PE	-5.25
Analyst	Buy
Dividends	n/a

Ask	22.23
Volume	554,275
Avg. Volume (20D)	766,733
Open	21.24
Previous Close	21.22
Day's Range	21.24 - 21.99
52-Week Range	9.90 - 27.20
Beta	0.54
Ex-Dividend Date	n/a

About VRDN

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol VRDN

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for VRDN stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Next Earnings Release

Viridian Therapeutics Inc. is scheduled to release its earnings on Nov 11, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

2 months ago

+6.02%

Viridian Therapeutics shares are trading higher af... Unlock content with Pro Subscription

4 months ago

+7.8%

Viridian Therapeutics shares are trading higher after the company announced positive long-term durability data from its THRIVE Phase 3 clinical trial of veligrotug in TED patients.

News

3 days ago · businesswire.com

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering, developing, and commercializing potential best-in-class medicines for s...

1 week ago · seekingalpha.com

Viridian Therapeutics: De-Risked Leadership In Thyroid Eye Disease

Viridian Therapeutics (VRDN) offers a differentiated next-gen therapy for Thyroid Eye Disease, targeting a large, underpenetrated market dominated by Amgen's Tepezza. VRDN-001 (veligrotug) demonstrate...

1 month ago · benzinga.com

These Analysts Revise Their Forecasts On Viridian Therapeutics Following Q2 Results

Viridian Therapeutics, Inc. VRDN reported upbeat results for the second quarter on Wednesday.

1 month ago · fool.com

Viridian (VRDN) Q2 Net Loss Widens 55%

1 month ago · zacks.com

Viridian Therapeutics, Inc. (VRDN) Reports Q2 Loss, Misses Revenue Estimates

Viridian Therapeutics, Inc. (VRDN) came out with a quarterly loss of $1 per share in line with the Zacks Consensus Estimate. This compares to a loss of $1.02 per share a year ago.

1 month ago · businesswire.com

Viridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2025 Financial Results

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing and commercializing potential best-in-class medicines for seriou...